- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.09. | Roth/MKM initiates Rapid Micro Biosystems stock with buy rating | 1 | Investing.com | ||
| 29.09. | Roth/MKM startet Coverage für Rapid Micro Biosystems mit "Buy"-Rating | 2 | Investing.com Deutsch | ||
| 24.09. | Rapid Micro Biosystems: Frühe Wachstumsphase mit klarem Margenfokus | 1 | Investing.com Deutsch | ||
| 07.08. | Rapid Micro Biosystems übertrifft Umsatzprognose für Q2 2026, doch Aktie gibt nach | 4 | Investing.com Deutsch | ||
| 07.08. | RAPID MICRO BIOSYSTEMS, INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 07.08. | Rapid Micro Biosystems reports mixed Q2 results; reaffirms FY26 outlook | 3 | Seeking Alpha | ||
| RAPID MICRO BIOSYSTEMS Aktie jetzt für 0€ handeln | |||||
| 07.08. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results | 775 | GlobeNewswire (Europe) | Reports second quarter 2026 total revenue of $8.1 million, representing 11% growth compared to the second quarter of 2025 Achieved a significant milestone with the 200th Growth Direct system placed... ► Artikel lesen | |
| 07.08. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.08. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 23.07. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026 | 3 | GlobeNewswire (USA) | ||
| 10.06. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 19.05. | Rapid Micro Biosystems prices $9.8M capital raise with up to $21.7M in additional warrant potential | 1 | Seeking Alpha | ||
| 19.05. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering | 2 | GlobeNewswire (USA) | ||
| 15.05. | RAPID MICRO BIOSYSTEMS, INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 13.05. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports First Quarter 2026 Financial Results | 788 | GlobeNewswire (Europe) | Reports first quarter 2026 total revenue of $8.0 million, representing 11% growth compared to the first quarter of 2025 Placed 6 Growth Direct systems in the first quarter 2026 compared to 3 systems... ► Artikel lesen | |
| 12.03. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct Platform | 885 | GlobeNewswire (Europe) | LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation... ► Artikel lesen | |
| 14.01. | After-Hours Biotech Rally: SXTC, RPID, TGTX Lead Gains On Revenue Updates, And FDA Milestones | 832 | AFX News | BEIJING (dpa-AFX) - Several biotechnology and pharmaceutical names posted notable gains in Tuesday's after-hours trading session, driven by corporate updates and investor enthusiasm around clinical... ► Artikel lesen | |
| 13.01. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue | 846 | GlobeNewswire (Europe) | Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period.Received record multi-system order in the fourth... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,623 | +0,81 % | Valneva meldet positive Phase-2-Daten für Shigellen-Impfstoff | Valneva hat mit seinem Impfstoffkandidaten S4V2 gegen Shigellose positive Ergebnisse aus zwei klinischen Phase-2-Studien erzielt. In einer US-amerikanischen Studie mit kontrollierter Infektion gesunder... ► Artikel lesen | |
| NOVAVAX | 9,050 | -0,88 % | Novavax, Inc.: Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights | Reports total revenue of $68 million for the third quarter of 2026Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 6,980 | +1,31 % | This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday | ||
| OCUGEN | 0,882 | +4,01 % | Ocugen im Check: OCU400-Deal mit Celairis - jetzt zählt die nächste Stufe | ||
| VIVORYON THERAPEUTICS | 0,728 | +2,82 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,317 | +3,93 % | 200 Prozent Ausbeute, 1 geplanter GMP-Partner: Warum NurExone und Made Scientific die Exosomenproduktion skalieren wollen | ||
| SAREPTA THERAPEUTICS | 14,580 | -0,82 % | Sarepta Therapeutics auf Guggenheim-Konferenz: Starker Cashflow finanziert breite Entwicklungspipeline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,068 | +2,83 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 10-Q, Quarterly Report | ||
| REDHILL BIOPHARMA | 0,375 | -0,03 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| MYRIAD GENETICS | 5,010 | -1,34 % | Myriad Genetics auf der UBS Global Healthcare Conference: Strategischer Schwenk zur Onkologie vertieft | ||
| MANNKIND | 3,801 | +0,42 % | Cantor Fitzgerald hebt Kursziel für MannKind wegen Tyvaso-Dynamik auf 10 US-Dollar an | ||
| ONCO-INNOVATIONS | 0,141 | +10,52 % | Redwood AI Corp.: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| NOVOCURE | 10,615 | +0,38 % | Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya for Brain Metastases from Non-Small Cell Lung Cancer | Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 5,950 | 0,00 % | Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028 | ||
| TRAWS PHARMA | 0,224 | -0,27 % | Traws Pharma, Inc. - S-1, General form for registration of securities |
Das Unternehmen RAPID MICRO BIOSYSTEMS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,006 (+0,84 %) liegt der Kurs bei 0,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPID MICRO BIOSYSTEMS INC finden Sie auf Wallstreet Online.